Vaccine Safety



With the ever-increasing volume in data and a growing number of new vaccines entering the market it has never been more important to leverage new technologies and methods to improve the efficiency and accuracy of pharmacovigilance for vaccines.  

This focussed vaccine safety and pharmacovigilance conference will allow you to listen and learn from key thought leaders in this space, as well as to showcase any solutions that are greatly needed in order to revolutionise and replace outdated ways of working.   Furthermore, escalating incidences of vaccine-refusal makes the importance of effective communication paramount, so join us to present your most successful strategies


Who Attends


• Pharma
• Biotech
• Regulatory Agencies
• Government
• Academics


Job Titles


• Vaccine Safety Lead
• Head of Vaccine Safety Evaluation
• Vaccine Safety Physician
• Regulatory Pharmacovigilance
• G.P.V. and EU Q.P.P.V
• Head of Vaccine safety Surveillance
• Clinical Safety & Pharmacovigilance

Who Should Sponsor?


• Consulting services
• Risk Management services
• IT Solution providers
• Mobile solutions / app developers
• Data solution providers
• CROs
• PR and communications firms


Vaccine Safety Conference, Tuesday 16 April 2019

Vaccine Safety Conference

Chair's opening remarks

Vaccine Communication – Risk Assessment and Communication of Safety

Dr Heidi Larson
Vaccine Safety Conference

Perceived and real risks of vaccines in Pregnancy

Dr Heidi Larson, Professor of Anthropology, Risk and Decision Science LSHTM
Dr Ed Lewin
Vaccine Safety Conference

Strategies to enhance vaccine acceptance in future generations

Ed Lewin, Research Professor, Milken Institute for Public Health, Georgetown UniversityDr Barbara Pahud, Associate Director, Vaccine and Treatment Evaluation Unit, Kansas City; Associate Professor of Pediatrics, Children’s Mercy Hospital, Kansas CityAdditional panelists TBC

Networking Coffee Break

Understanding the System

Dr Daniel Salmon
Vaccine Safety Conference

Overview of US vaccine safety infrastructure

Dr Daniel Salmon, Director, Institute for Vaccine Safety, Johns Hopkins Bloomberg School of Public Health
Dr Walter Straus
Vaccine Safety Conference

Panel: Does industry believe in the value of Sentinel?

Dr Walter Straus, Associate Vice President, Therapeutic Area Head, Clinical Safety and Risk Management, Merck Research Laboratories Dr Jens-Ulrich Stegmann, Vice President Head Clinical Safety and Pharmacovigilance, GSKAdditional panelists TBC

Networking Lunch & Poster Session

Dr Rebecca Chandler
Vaccine Safety Conference

Updates from the Uppsala Monitoring Centre

Dr Rebecca Chandler, Research Physician, Uppsala Monitoring Center

Emerging Science in Vaccine Safety

Vaccine Safety Conference

Development of new statistical methods for evaluating the comparative safety of different childhood vaccine schedules

Vaccine Safety Conference

Keeping up with changing regulatory demands in vaccine safety monitoring


Networking Coffee Break

Dr Steven Jacobsen
Vaccine Safety Conference

Challenges in post-licensure safety studies using real world data. Example: Hepatitis b vaccine

Dr Steven Jacobsen, Senior Director of Research, Kaiser Permanente Southern California
Dr Jens-Ulrich Stegmann
Vaccine Safety Conference

Joint presentation: Emerging innovations in vaccine safety science, perspectives from academia and industry

Dr Miriam Sturkenboom, Professor, Department of Global Health, Julius Center, University Medical Center UtrechtDr Jens-Ulrich Stegmann, Vice President Head Clinical Safety and Pharmacovigilance, GSK
Dr Jennifer Nelson
Vaccine Safety Conference

How big data can lead to safer drugs and vaccines

Dr Jennifer Nelson, Director of Biostatistics & Senior Investigator, Biostatistics Unit, Kaiser Permanente Washington Health Research Institute

Chair’s Closing Remarks per co-lo and Close of Congress Day 2


Off-site Networking Drinks, follow the congress team

last published: 23/Nov/18 12:35

Vaccine Safety Conference, Wednesday 17 April 2019

Vaccine Safety Conference

Chair's opening remarks

Vaccine Safety Case Studies

Dr Fernanda Tavares Da Silva
Vaccine Safety Conference

Safety monitoring of vaccines targeting special populations (e.g. elderly, maternal): Current challenges and approaches

Fernanda Tavares da Silva, Senior Director, Head of Safety Evaluation & Risk Management, R&D Center GSK Vaccines
Dr Wendy Carr
Vaccine Safety Conference

Joint presentation: Challenges in trial design, implementation and safety assessment of an Ebola vaccine under clinical development

Dr Wendy Carr, STRIVE Ebola Vaccine Trial Regulatory Oversight Lead, CDCAdditional Speakers TBC*
Dr Wendy Carr, Acting Design & Oversight Team Lead Clinical Research Branch, US Centers for Disease Control and Prevention

Networking Coffee Break

Vaccine Safety Conference

Considerations for safety assessment of a new class of mRNA vaccines

Dr Inna Ovsyannikova
Vaccine Safety Conference

Adversomics: a glimpse into the future

Dr Inna Ovsyannikova, Professor of Medicine, Mayo Clinic

Networking Lunch & Poster Session


Gregory Poland

Chair's opening remarks

Dr Gregory A. Poland, Director of Mayo Vaccine Research Group, Mayo Clinic
Paul Offit
Dr Saad Omer

A framework for a comprehensive maternal immunization platform

  • Evidence for current immunization recommendations
  • Maternal vaccines in development
  • The need for evidence-based interventions at the practice, provider, and patient levels to ensure higher vaccination levels
Dr Timothy Cooke

Chair Closing Remarks and End of Congress

last published: 23/Nov/18 12:35


Sign Up for Event Updates

Get Involved At World Vaccine Congress Washington


To Sponsor Or Exhibit

Marc Rhys-Evans
+44 20 7827 5945




To Register

Tayyab Abbasi
+44 20 7092 1210




Press Relations

Karina Kusova
+44 20 7092 1071